IBRX280121P00010000
IBRX Jan 21 2028 10.00 Put
optionOPRA
EODOct 15, 2026
3.50USD+3.245%(+0.11)50Vol3,806OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
10
Expiration
Jan 21, 2028
DTE
458d
Moneyness
ITM
Intrinsic
$1.52
IBRX 10 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.93 | +78.85% | 176 | 1,656 |
| Oct 30, 2026 | 10d | $1.15 | +76.92% | 2 | 259 |
| Nov 6, 2026 | 17d | $1.47 | +14.84% | 2 | 125 |
| Nov 13, 2026 | 24d | $1.05 | -12.50% | 4 | 11 |
| Nov 20, 2026 | 31d | $1.48 | +28.70% | 99 | 735 |
| Nov 27, 2026 | 38d | $1.52 | -12.14% | 1 | 1 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $2.06 | +1.48% | 50 | 6,506 |
| Mar 19, 2027 | 150d | $2.40 | -4.00% | 10 | 68 |
| Apr 16, 2027 | 178d | $4.80 | +0.00% | 10 | 10 |
| May 21, 2027 | 213d | $3.00 | -36.17% | 10 | 164 |
| Aug 20, 2027 | 304d | $4.70 | +0.00% | 1 | 16 |
| Nov 19, 2027 | 395d | $2.50 | +0.00% | 1 | 1 |
| Jan 21, 2028 | 458d | $3.50 | +3.24% | 50 | 3,806 |
| Mar 17, 2028 | 514d | $4.00 | -6.32% | 1 | 20 |
| Jan 19, 2029 | 822d | $4.45 | +7.23% | 1 | 89 |
IBRX Nearby Strikes · Jan 21, 2028
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 3.5 P | $0.55 | -73.17% | 2 | 11 | OTM |
| 4 P | $1.32 | -37.14% | 1 | 21 | OTM |
| 4.5 P | $1.35 | -38.07% | 234 | 250 | OTM |
| 5 P | $0.98 | +8.89% | 1 | 974 | OTM |
| 5.5 P | $1.58 | +17.04% | 10 | 3,931 | OTM |
| 7.5 P | $1.95 | -9.30% | 125 | 9,702 | OTM |
| 10 P | $3.50 | +3.24% | 50 | 3,806 | ITM |
| 12 P | $4.98 | -4.23% | 10 | 42 | ITM |
| 15 P | $7.25 | -14.71% | 1 | 676 | ITM |
| 17 P | $8.75 | -1.02% | 5 | 8 | ITM |
| 20 P | $14.10 | +6.82% | 2 | 37 | ITM |
| 22 P | $13.23 | +0.84% | 5 | 56 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.